What is Bloom Burton's Estimate for Cybin FY2025 Earnings?

Cybin Inc. (NYSE:CYBN - Free Report) - Equities researchers at Bloom Burton cut their FY2025 EPS estimates for Cybin in a research note issued to investors on Tuesday, November 19th. Bloom Burton analyst D. Martin now anticipates that the company will post earnings of ($6.12) per share for the year, down from their prior forecast of ($4.46). The consensus estimate for Cybin's current full-year earnings is ($3.37) per share. Bloom Burton also issued estimates for Cybin's FY2026 earnings at ($6.51) EPS.

A number of other equities analysts have also commented on CYBN. Canaccord Genuity Group reduced their price target on shares of Cybin from $96.00 to $86.00 and set a "buy" rating on the stock in a research report on Thursday, November 14th. Cantor Fitzgerald restated an "overweight" rating on shares of Cybin in a research report on Wednesday, July 31st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $190.00 price target on shares of Cybin in a report on Monday.

Cybin Stock Down 3.3 %

Shares of NYSE:CYBN traded down $0.34 on Friday, hitting $9.82. The stock had a trading volume of 883,413 shares, compared to its average volume of 184,886. The company has a 50 day moving average of $9.57. Cybin has a twelve month low of $6.50 and a twelve month high of $21.66. The company has a market cap of $196.32 million, a P/E ratio of -1.44 and a beta of 0.38.

Institutional Trading of Cybin

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sanctuary Advisors LLC acquired a new stake in Cybin in the second quarter worth about $36,000. AdvisorShares Investments LLC grew its position in shares of Cybin by 13.4% during the 2nd quarter. AdvisorShares Investments LLC now owns 1,865,217 shares of the company's stock worth $494,000 after buying an additional 220,403 shares during the period. PEAK6 Investments LLC bought a new stake in shares of Cybin during the first quarter worth approximately $95,000. AWM Investment Company Inc. acquired a new position in Cybin in the first quarter valued at approximately $930,000. Finally, Rosalind Advisors Inc. boosted its stake in Cybin by 38.3% in the second quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company's stock valued at $5,230,000 after acquiring an additional 5,340,000 shares during the last quarter. Institutional investors and hedge funds own 17.94% of the company's stock.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.